Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BHVN Biohaven Pharmaceutical Holding Co Ltd.

Market Closed 07-17 16:00:00 EDT

15.44

+1.27

+8.96%

盘后14.97

-0.47-3.05%

19:59 EDT

High15.51	Low13.62	Vol3.51M
Open13.74	D1 Closing14.17	Amplitude13.34%
Mkt Cap2.32B	Tradable Cap1.91B	Total Shares150.42M
T/O53.24M	T/O Rate2.83%	Tradable Shares124.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BHVN","market":"US","secType":"STK","nameCN":"Biohaven Pharmaceutical Holding Co Ltd.","latestPrice":15.44,"timestamp":1784318400000,"preClose":14.17,"halted":0,"volume":3506223,"hourTrading":{"tag":"盘后","latestPrice":14.9684,"preClose":15.44,"latestTime":"19:59 EDT","volume":37462,"amount":578395.7543,"timestamp":1784332766330,"change":-0.4716,"changeRate":-0.030544,"amplitude":0.030544},"delay":0,"changeRate":0.08962597035991529,"floatShares":124000000,"shares":150417084,"eps":-5.440705,"marketStatus":"Market Closed","change":1.27,"latestTime":"07-17 16:00:00 EDT","open":13.74,"high":15.51,"low":13.62,"amount":53241340.591299,"amplitude":0.13338,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.440705,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1784534400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NYSE","adjPreClose":14.17,"preHourTrading":{"tag":"盘前","latestPrice":14.01,"preClose":14.17,"latestTime":"07:31 EDT","volume":1294,"amount":18187.071656,"timestamp":1784287865723,"change":-0.16,"changeRate":-0.011291,"amplitude":0.053056},"postHourTrading":{"tag":"盘后","latestPrice":14.9684,"preClose":15.44,"latestTime":"19:59 EDT","volume":37462,"amount":578395.7543,"timestamp":1784332766330,"change":-0.4716,"changeRate":-0.030544,"amplitude":0.030544},"volumeRatio":2.199018595262634,"optionData":{"bulkOrders":[{"symbol":"BHVN","call":true,"expireDate":1784260800000,"strike":"15.0","timestamp":1784298897142,"price":0.3,"volume":1200,"amount":36000,"type":"-"}]},"impliedVol":1.0395,"impliedVolPercentile":0.494},"requestUrl":"/m/hq/s/BHVN/wiki","defaultTab":"wiki","newsList":[{"id":"2652233697","title":"Biohaven Files Form 3 for Chief Legal Officer Warren Karl Volles","url":"https://stock-news.laohu8.com/highlight/detail?id=2652233697","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652233697?lang=en_us&edition=fundamental","pubTime":"2026-07-18 06:01","pubTimestamp":1784325664,"startTime":"0","endTime":"0","summary":"Biohaven files Form 3 for Chief Legal Officer Warren Karl VollesBiohaven Chief Legal Officer Warren Karl Volles reported 248,212 common shares, with stock options covering 731,000 shares in an initial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL7r0Qs1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","LU1093756168.USD","LU1093756325.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650972712","title":"Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2650972712","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650972712?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:27","pubTimestamp":1783632476,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) said late Thursday that Chief Scientific Officer Bruce Car will retire from the role and transition to the newly created position of chief innovation officer, effective July 13.Car wil","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BHVN","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650972271","title":"Biohaven’s Bruce Car retires as chief scientific officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2650972271","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650972271?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:05","pubTimestamp":1783631116,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohavens-bruce-car-retires-as-chief-scientific-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohavens-bruce-car-retires-as-chief-scientific-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BHVN","LU1093756325.SGD","LU1093756168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650972693","title":"Biohaven Promotes David Pirman to EVP, Head of Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2650972693","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650972693?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:00","pubTimestamp":1783630824,"startTime":"0","endTime":"0","summary":"Biohaven promotes David Pirman to EVP, head of discoveryBiohaven promoted David Pirman to executive vice president, head of discovery to run internal drug discovery and oversee research programs.Bruce","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL3ySP0F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1093756325.SGD","LU1093756168.USD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650697263","title":"Press Release: Biohaven Announces Scientific Leadership Transitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2650697263","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650697263?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:00","pubTimestamp":1783630800,"startTime":"0","endTime":"0","summary":"-- David Pirman, Ph.D. promoted to Executive Vice President and Head of. -- Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role. as Chief Innovation Officer focusing on external collaborations. -- Warren Volles, General Counsel and Chief Legal Officer, also designated","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BHVN","BK4139","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648545350","title":"Analysts’ Top Healthcare Picks: Heart Test Laboratories, Inc. (HSCS), Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648545350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648545350?lang=en_us&edition=fundamental","pubTime":"2026-07-01 21:00","pubTimestamp":1782910821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heart Test Laboratories, Inc. (HSCS) and Biohaven Lt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-heart-test-laboratories-inc-hscs-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-heart-test-laboratories-inc-hscs-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","HCSG","LABU","BK4139","BK4581","LU0128526141.USD","BK4082","BHVN","BK4137","BK4588","LU1093756168.USD","XBI","BK4585","HSCS","LU1093756325.SGD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558226","title":"Biohaven announces completion of enrollment in RISE3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558226?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:35","pubTimestamp":1782819353,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled studies evaluatin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-announces-completion-of-enrollment-in-rise3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-announces-completion-of-enrollment-in-rise3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","LU1093756325.SGD","BK4139","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647939558","title":"Biohaven - Completes Enrollment in Rise3 Pivotal Phase 2/3 Focal Epilepsy Study with Opakalim","url":"https://stock-news.laohu8.com/highlight/detail?id=2647939558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647939558?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:31","pubTimestamp":1782819089,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1093756168.USD","BHVN","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558607","title":"Biohaven - Top-line Results from Rise3 Study Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558607?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:31","pubTimestamp":1782819089,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320AE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1093756325.SGD","LU1093756168.USD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558670","title":"Biohaven Completes Enrollment in RISE3 Pivotal Opakalim Focal Epilepsy Trial, Data Due 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558670","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558670?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:30","pubTimestamp":1782819026,"startTime":"0","endTime":"0","summary":"Biohaven completes enrollment in RISE3 pivotal opakalim focal epilepsy trial, data due 2H 2026Biohaven completed enrollment in RISE3, a pivotal Phase 2/3 trial of opakalim as add-on therapy for refrac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL2MrJk8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","LU1093756325.SGD","LU1093756168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647830984","title":"Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at Bofa","url":"https://stock-news.laohu8.com/highlight/detail?id=2647830984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647830984?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:49","pubTimestamp":1782755340,"startTime":"0","endTime":"0","summary":"Shares of Biohaven retreated after they were downgraded by analysts at Bank of America on concerns about the upcoming readout from a Phase 3 trial for the company's epilepsy drug, known as Opakalim.The stock was down 6.3% at $14.84 in Monday afternoon trading. Shares have risen 31% this year.Even under the best case scenario, the analysts wrote, data for Biohaven's drug is likely to be undifferentiated when compared to Xenon Pharmaceuticals' investigative epilepsy treatment, known as azetukalnar.  Undifferentiated data would cast doubt on the consensus view that Biohaven could reach $1 billion in peak sales for the drug, they added.Biohaven's drug is identified Opakalim on the company's web site.\"Uncompelling Kv data could pressure shares given the company's cash runway concerns and the other sole 2026 catalyst  carries low derisking value,\" the analysts added.They downgraded the stock to underperform from neutral and cut its price target to $11 from $12.Write to Elias Schisgall at eli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4139","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647703303","title":"Biohaven falls -9.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647703303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647703303?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:05","pubTimestamp":1782741929,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) is down -9.8%, or -$1.55 to $14.28. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-falls-9-8-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-falls-9-8-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BHVN","LU1093756325.SGD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379322","title":"Biohaven Cut to Underperform from Neutral by B of a Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379322","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647379322?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:53","pubTimestamp":1782733980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 07:53 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","BK4139","LU1093756325.SGD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647767403","title":"BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2647767403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647767403?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:41","pubTimestamp":1782733317,"startTime":"0","endTime":"0","summary":"BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BHVN","LU1093756325.SGD","LU1093756168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647761213","title":"Biohaven Starts Pivotal Phase 3 Trial of Bhv-1300 in Graves' Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2647761213","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647761213?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732647,"startTime":"0","endTime":"0","summary":"Biohaven starts pivotal Phase 3 trial of BHV-1300 in Graves' diseaseBiohaven began a pivotal Phase 3 trial of BHV-1300 in Graves’ disease, marking the first patient enrolled on June 29, 2026.Prior ear","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL5YXBTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","LU1093756325.SGD","LU1093756168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647737697","title":"Biohaven Advances a New Class of Precision Immunology Therapies: First Mode Extracellular Protein Degrader, Bhv-1300, Begins Phase 3 Pivotal Trial in Graves' Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2647737697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647737697?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA3BXV5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756168.USD","BHVN","BK4139","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647375106","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647375106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647375106?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:50","pubTimestamp":1782730248,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-biohaven-ltd-bhvn-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-biohaven-ltd-bhvn-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0320765992.SGD","LU0128526141.USD","BK4585","IE00B2B36J28.USD","BK4548","IE0002141913.USD","LU1093756325.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","LU0109394709.USD","ALNY","IE0009355771.USD","BK4137","IE00B4R5TH58.HKD","LU0889565916.HKD","XLV","HCSG","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK4581","LU0114720955.EUR","LABU","LU0029874061.USD","BHVN","LU0882574055.USD","XBI","BK4139","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646632673","title":"Biohaven rises 7.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646632673","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646632673?lang=en_us&edition=fundamental","pubTime":"2026-06-26 22:07","pubTimestamp":1782482824,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) is up 7.4%, or $1.13 to $16.47. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-rises-7-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-rises-7-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1093756325.SGD","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646133434","title":"U.S. Research Roundup-american Tower, H.B. Fuller Company, TD Synnex","url":"https://stock-news.laohu8.com/highlight/detail?id=2646133434","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646133434?lang=en_us&edition=fundamental","pubTime":"2026-06-26 15:06","pubTimestamp":1782457590,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-American Tower, H.B. Fuller Company, TD SynnexJune 26 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL4N42Y0ET:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTR","LU0648001328.SGD","ALLY","ALK","BNY","BAC","TECH","CMC","GH","ESTC","EPR","AALG","CTSH","DRI","CUZ","AMT","AIT","FDXF","CROX","AAL","BNED","IE00BD4GTW91.USD","FTH","SNX","LU0347712357.USD","AVAV","LU2413666699.HKD","CALY","GOLF","ALGT","CSX","BHVN","BRO","AR","DAL","DYN","EXPD","A","ESS","ACA","CNTB","AVXX","BDC","ACNB","AMH","LU0477156953.USD","LU0011850046.USD","AMAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646048238","title":"Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2646048238","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646048238?lang=en_us&edition=fundamental","pubTime":"2026-06-25 23:26","pubTimestamp":1782401212,"startTime":"0","endTime":"0","summary":"Biohaven's  troriluzole to treat neurodegenerative diseases could see up to a 100% upside if the company overcomes regulatory hurdles amid the US Food and Drug Administration's more sponsor-friendly stance, RBC Capital Markets said in a Thursday note.Considering shares as undervalued on epilepsy and degrader programs, the analysts said the drug candidate could make for an even more interesting setup for the stock.According to the note, factors that could support FDA leniency for troriluzole include its largely safe and well-tolerated data and design to target a rare disease with no approved treatments.RBC reiterated its outperform rating on the stock and adjusted its price target to $22 from $23.Price: 15.51, Change: +0.55, Percent Change: +3.68","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BHVN","LU1093756168.USD","LU1093756325.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biohaven.com","stockEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.1336},{"period":"3month","weight":0.4062},{"period":"6month","weight":0.175},{"period":"1year","weight":0.0218},{"period":"ytd","weight":0.3676}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.0467},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1835},{"period":"ytd","weight":0.09}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.071849},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.026101},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.120539},{"month":4,"riseRate":0.555556,"avgChangeRate":0.027819},{"month":5,"riseRate":0.666667,"avgChangeRate":0.144578},{"month":6,"riseRate":0.6,"avgChangeRate":0.085557},{"month":7,"riseRate":0.6,"avgChangeRate":0.013483},{"month":8,"riseRate":0.666667,"avgChangeRate":0.043364},{"month":9,"riseRate":0.777778,"avgChangeRate":0.09598},{"month":10,"riseRate":0.555556,"avgChangeRate":-0.072057},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.042561},{"month":12,"riseRate":0.555556,"avgChangeRate":0.054983}],"exchange":"NYSE","name":"Biohaven Pharmaceutical Holding Co Ltd.","nameEN":"Biohaven Pharmaceutical Holding Co Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biohaven Pharmaceutical Holding Co Ltd.,BHVN,Biohaven Pharmaceutical Holding Co Ltd.股票,Biohaven Pharmaceutical Holding Co Ltd.股票老虎,Biohaven Pharmaceutical Holding Co Ltd.股票老虎国际,Biohaven Pharmaceutical Holding Co Ltd.行情,Biohaven Pharmaceutical Holding Co Ltd.股票行情,Biohaven Pharmaceutical Holding Co Ltd.股价,Biohaven Pharmaceutical Holding Co Ltd.股市,Biohaven Pharmaceutical Holding Co Ltd.股票价格,Biohaven Pharmaceutical Holding Co Ltd.股票交易,Biohaven Pharmaceutical Holding Co Ltd.股票购买,Biohaven Pharmaceutical Holding Co Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}